« GSK: More Cuts Coming |
| A Pile of Malaria Leads For the Taking »
February 1, 2010
And on the Carl Icahn Front. . .
He's back with three more directors nominated for the company's board. There are two Icahnians there already, and this round of proxy voting will say a lot about whether shareholders think that taking Biogen down the road that Imclone went is a good thing or not. Stay tuned. . .
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- A Last Summer Day Off
- The Early FDA
- Drug Repurposing
- The Smallest Drugs
- Life Is Too Short For Some Journal Feeds
- A New Look at Phenotypic Screening
- Small Molecules - Really, Really Small
- InterMune Bought